Testing GW01-200 tablets in advanced cancer patients
Part of Cancer clinical trials.
This is an early-stage trial testing a new drug called GW01-200 in people with advanced solid tumors or blood cancers that have gotten worse despite standard treatment. The study aims to find the right dose and see how well the drug works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic cancer (spread to other parts of the body) that got worse after standard treatment, or you cannot tolerate standard treatment, or no standard treatment exists for your cancer type
- You have at least one measurable tumor lesion that can be tracked on imaging
- Your overall health and ability to perform daily activities are good (ECOG score 0 or 1)
- Your life expectancy is at least 3 months
- Your organ and bone marrow function are adequate (blood counts and kidney/liver function are acceptable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new oral drug (WJ22096) for people with advanced solid tumors that have stopped responding to or cannot tolerate standard treatments. It may be an option if you are generally healthy enough to take part.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new oral drug, GW5282, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug can shrink tumors or stop them from growing.
This early-phase study tests whether WJB001 capsules can treat advanced solid tumors in adults whose cancer has progressed after standard treatment (or who cannot take standard treatment). It also studies side effects and whether the drug can work for certain tumor types and genetic markers.
This trial tests an experimental oral tablet (LIT-00814) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and to find the best dose.
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.